Sandoz

Key takeawaysThe Cambridge center will enhance the development of drug-device combinations, crucial for effective medication delivery. Significant investment in local talent is expected...

Key InsightsSandoz's strategy of expanding its biosimilars portfolio is proving successful, as evidenced by substantial sales growth. Europe's generics market remains a strong...

Key TakeawaysSandoz introduces the first FDA-approved generic paclitaxel, marking a key milestone in metastatic breast cancer treatment. The single-dose 100 mg vial simplifies...

Sandoz, the global leader in generic and biosimilar medicines, has announced the launch of Pyzchiva® (ustekinumab) across Europe, marking a significant advancement in the...

Sandoz, a global leader in generic and biosimilar medicines, announced that the U.S. Food and Drug Administration (FDA) has approved Enzeevu™ (aflibercept-abzv) for neovascular...

Biosimilars Wyost® and Jubbonti® have received landmark approval from the European Commission (EC), marking the first biosimilar versions of denosumab to be authorized in...

The FDA has approved two interchangeable denosumab biosimilars in managing primary and secondary bone loss, denosumab-bddz (Wyost) and denosumab-bddz (Jubbonti), developed by Sandoz and...

Tyruko has been indicated as a single disease-modifying therapy (DMT) for adults diagnosed with highly active Relapsing-Remitting Multiple Sclerosis (RRMS), a designation also approved...

Novartis successfully carried out the Sandoz Spin-off, marking the conclusion of its strategic transformation into prominent pharmaceuticals. This separation was executed through a dividend-in-kind...